Valens GroWorks Corp. (TSXV:VGW, OTCQX:VGWCF) (the “Company”, “Valens” or “The Valens Company”), a vertically integrated provider of industry leading extraction products and services, including a diverse suite of extraction methodologies, next generation cannabinoid delivery formats and an ISO 17025 accredited analytical lab, announced today that the TSX Venture Exchange (the “TSXV”) has approved its notice of intention to make a normal course issuer bid for its common shares (“Shares”) as appropriate opportunities arise from time to time.  Valens’ normal course issuer bid will be made in accordance with the policies of the TSXV.  Valens may purchase its Shares during the period from December 19, 2019 to December 18, 2020.

Pursuant to the notice and subject to the market price of its Shares and other considerations, Valens may acquire over the next 12 months up to 6,275,204 Shares, representing 5% of the outstanding Shares, for cancellation. There are 125,504,096 Shares outstanding as of December 12, 2019.  Any purchases will be made at market prices through the facilities of the TSXV. Valens believes that the purchase of its outstanding Shares may be an appropriate use of its resources over the next 12 months, based upon the market price of its Shares during such period. AltaCorp Capital Inc. has been appointed by Valens as broker to conduct the normal course issuer bid.


About The Valens Company

The Valens Company is a global leader in the end-to-end development and manufacturing of innovative, cannabinoid-based products. The Company is focused on being the partner of choice for leading Canadian and international cannabis brands by providing best-in-class, proprietary services including CO2, ethanol, hydrocarbon, solvent-less and terpene extraction, analytical testing, formulation and white label product development and manufacturing.  Valens is the largest third-party extraction company in Canada with an annual capacity of 425,000 kg of dried cannabis and hemp biomass at our purpose-built facility in Kelowna, British Columbia which is in the process of becoming European Union (EU) Good Manufacturing Practices (GMP) compliant.  The Valens Company currently offers a wide range of product formats, including tinctures, two-piece caps, soft gels, oral sprays and vape pens as well as beverages, concentrates, topicals, edibles, injectables, natural health products and has a strong pipeline of next generation products in development for future release.  Finally, the Company’s wholly-owned subsidiary Valens Labs is a Health Canada licensed ISO 17025 accredited cannabis testing lab providing sector-leading analytical services and has partnered with Thermo Fisher Scientific to develop a Centre of Excellence in Plant-Based Science. Effective at the start of trading on December 19, 2019, The Valens Company will trade on the TSXV under the ticker VLNS. The Company expects to formally change its name in due course (with its ticker changing on the OTCQX once final regulatory approvals are received).  For more information, please visit http://thevalenscompany.com.  The Company’s investor deck can be found specifically at http://thevalenscompany.com/investors/.

Notice regarding Forward Looking Statements

This news release contains certain “forward-looking statements” within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as “anticipates”, “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed”, “positioned” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

The TSXV or other regulatory authority has not reviewed, approved or disapproved the contents of this press release. We seek Safe Harbour.

Click here to connect with Valens GroWorks Corp (TSXV:VGW, OTCQX:VGWCF) for an Investor Presentation.

Source

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or “the Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced the hiring of CPG industry veteran Ty Gent as the Company’s new Chief Operating Officer (“COO”). As COO, Gent will be responsible for operational consistency and efficiency across markets and implementation of structural enhancements to facilitate scaling.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210119005322/en/

Keep reading... Show less

HempFusion Wellness Inc. (TSX:CBD.U) (“ HempFusion ” or the “ Company ”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that its wholly owned subsidiary, Probulin Probiotics, LLC (“ Probulin ”), has increased its product selection in certain brick and mortar locations and expanded its distribution on Amazon through a unique eCommerce store within the Amazon platform. The broader product selection is available in major brick and mortar stores including Sprouts and Fresh Thyme and includes the Company’s new Probulin Total Care Immune product.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210119005411/en/

Keep reading... Show less

 MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the “Company”, “MustGrow”) is pleased to report third party confirmatory studies that the active ingredient in MustGrow’s mustard plant-based technology, Allyl Isothiocyanate (“AITC”), has a positive impact on soil health, contributing to the environmental and ecological security of both our plant-based food supply and the planet. Application of natural AITC returns organic plant material to the soil through its pre-plant treatment process as a potential alternative to using synthetic chemicals.

Soil micro-organisms play an important role in soil fertility and plant health, contributing to natural soil processes including the formation of organic matter and nutrient transformation. Human activities, including chemical pesticide use, can adversely impact the soil microbial diversity and structure.

Keep reading... Show less

Heritage Cannabis Holdings Corp. (CSE: CANN) (OTCQX: HERTF) (“Heritage” or the “Company”), today announced that its subsidiary CannaCure Corp. (“CannaCure”) has entered into a binding letter of intent with Entourage Participações S.A. (“Entourage Phytolab”) for a three-year extraction and finished product supply agreement (the “Agreement”) for the distribution of pharmaceutical products in Brazil.

Under the terms of the Agreement, Heritage will supply to Entourage Phytolab, hemp-derived CBD dominant extract, cannabis-derived THC dominant extract, and hemp-derived CBD 25 mg softgels and cannabis-derived THC dominant 2.5 and 5.0 mg softgels.

Keep reading... Show less

Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant”) or (the “Company”) Is pleased to announce its partially owned subsidiary NeonMind (CSE: NEON) (“NeonMind”) has common shares now trading on the Frankfurt Stock Exchange (the “FSE”) under the symbol “6UF”. As a result, NeonMind’s common shares are now cross-listed on the Canadian Securities Exchange and the FSE. Shares of Better Plant are available on the FSE under the symbol “YG3”.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/6377/72301_betterplanta.jpg

Keep reading... Show less